Curis shares rise 12.39% intraday after presenting emavusertib clinical data at SNO meeting.

Curis (NASDAQ: CRIS) surged 12.39% intraday trading following the announcement that the company will present clinical and preclinical data on emavusertib, its IRAK4 inhibitor, at the 30th Annual Society for Neuro-Oncology (SNO) Meeting. The presentations, scheduled for November 21–23, 2025, include poster and oral sessions detailing preliminary efficacy and safety results in relapsed/refractory primary and secondary central nervous system lymphoma patients treated with emavusertib and ibrutinib. The data highlights progress in the TakeAim Lymphoma Phase 1/2 trial and preclinical research on melanoma brain metastases, reinforcing the drug’s potential in neuro-oncology. The news was deemed relevant and bullish, aligning with the stock’s upward trajectory as investors reacted positively to the clinical advancements.